These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22247043)

  • 1. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
    Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
    ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
    [No Abstract]   [Full Text] [Related]  

  • 2. Multimerized CHR-derived peptides as HIV-1 fusion inhibitors.
    Nomura W; Hashimoto C; Suzuki T; Ohashi N; Fujino M; Murakami T; Yamamoto N; Tamamura H
    Bioorg Med Chem; 2013 Aug; 21(15):4452-8. PubMed ID: 23800723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
    Mzoughi O; Gaston F; Granados GC; Lakhdar-Ghazal F; Giralt E; Bahraoui E
    ChemMedChem; 2010 Nov; 5(11):1907-18. PubMed ID: 20922745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.
    Oishi S; Ito S; Nishikawa H; Watanabe K; Tanaka M; Ohno H; Izumi K; Sakagami Y; Kodama E; Matsuoka M; Fujii N
    J Med Chem; 2008 Feb; 51(3):388-91. PubMed ID: 18197613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimeric C34 Derivatives Linked through Disulfide Bridges as New HIV-1 Fusion Inhibitors.
    Kobayakawa T; Ebihara K; Honda Y; Fujino M; Nomura W; Yamamoto N; Murakami T; Tamamura H
    Chembiochem; 2019 Aug; 20(16):2101-2108. PubMed ID: 31012222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E; Hummer G; Bewley CA; Clore GM
    J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.
    Lai W; Wang C; Yan J; Liu H; Zhang W; Lin B; Xi Z
    Bioorg Med Chem; 2020 Feb; 28(4):115214. PubMed ID: 31932193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG; Jia QY; Liu KL
    Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L; Gochin M; Liu K
    Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
    Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
    Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.
    Stewart KD; Huth JR; Ng TI; McDaniel K; Hutchinson RN; Stoll VS; Mendoza RR; Matayoshi ED; Carrick R; Mo H; Severin J; Walter K; Richardson PL; Barrett LW; Meadows R; Anderson S; Kohlbrenner W; Maring C; Kempf DJ; Molla A; Olejniczak ET
    Bioorg Med Chem Lett; 2010 Jan; 20(2):612-7. PubMed ID: 20004576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
    J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
    Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F
    Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.
    Otaka A; Nakamura M; Nameki D; Kodama E; Uchiyama S; Nakamura S; Nakano H; Tamamura H; Kobayashi Y; Matsuoka M; Fujii N
    Angew Chem Int Ed Engl; 2002 Aug; 41(16):2937-40. PubMed ID: 12203417
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
    Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41.
    Jiang S; Tala SR; Lu H; Zou P; Avan I; Ibrahim TS; Abo-Dya NE; Abdelmajeid A; Debnath AK; Katritzky AR
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6895-8. PubMed ID: 21978673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.
    Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH
    PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice.
    Stoddart CA; Nault G; Galkina SA; Thibaudeau K; Bakis P; Bousquet-Gagnon N; Robitaille M; Bellomo M; Paradis V; Liscourt P; Lobach A; Rivard ME; Ptak RG; Mankowski MK; Bridon D; Quraishi O
    J Biol Chem; 2008 Dec; 283(49):34045-52. PubMed ID: 18809675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.
    Kliger Y; Shai Y
    J Mol Biol; 2000 Jan; 295(2):163-8. PubMed ID: 10623516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.